Skip to main content
SpringerLink
Log in

HPV-Impfung

Wie geht es weiter?

  • TOPIC 2 • hpv-impfung
  • Published:
best practice onkologie Aims and scope

Zusammenfassung

Durch die bahnbrechenden Arbeiten von Prof. Harald zur Hausen gilt es als bewiesen, dass ein ursächlicher Zusammenhang zwischen einer persistierenden Infektion mit bestimmten Untergruppen von humanen Papillomaviren (HPV) und der Entwicklung von Zervixkarzinomen und ihren Vorläuferläsionen, den sog. Dysplasien bzw. zervikalen intraepithelialen Neoplasien (CIN), besteht. Bislang wurden mehr als 130 HPV-Typen identifiziert, von denen mehr als 40 genitale Infektionen verursachen.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Literatur

  1. Basemann JG, Koutsky LA (2005) The epidemiology of human papillomavirus infections. J Clin Virol 32 (Suppl 1): 16–24

    Article  Google Scholar 

  2. Klug SJ, Hukelmann M, Hollwitz B et al (2007) Prevalence of human papillomavirus types in women screened by cytology in Germany. J Med Virol 79: 616–625

    Article  PubMed  Google Scholar 

  3. Munoz N, Bosch FX, Sanjose S de et al (2003) Epidemilogic classification of human papillomavirus types associated with cervical cancer. N Engl J Med 348: 518–527

    Article  PubMed  Google Scholar 

  4. Statistisches Bundesamt (2005) Gesundheitswesen, Todesursachen in Deutschland 2004, Fachserie 12/Reihe 4, Statistisches Bundesamt 2005

  5. Gross G, Ikenberg H, Gissmann L, Hagedorn M (1985) Papillomavirus infection of the anogenital region: correlation between histolgy, clinical picture, and virus type. Proposal of a new nomenciature. J Invest Dermatol 85: 147–152

    Article  PubMed  CAS  Google Scholar 

  6. Koutsky LA, Ault KA, Wheeler CM et al (2006) Effiacy of human papillomavirus-16 vaccine to prevent cervical intraepithelial neoplasia: a randomized controlled trial. Obstet Gynecol 107: 18–27

    Article  PubMed  Google Scholar 

  7. Mao C, Koutsky LA, Ault KA et al (2006) Effiacy of human papillomavirus-16 vaccine to prevent cervical intraepithelial neoplasia: a randomized controlled trial. Obstet Gynecol 107: 18–27

    Article  PubMed  Google Scholar 

  8. Harper DM, Franco EL, Wheeler C et al (2004) Effiacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial. Lancet 364 (9447): 1757–1765

    Article  PubMed  CAS  Google Scholar 

  9. Paavonen J, Jenkins D, Bosch FX et al (2007) Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlles trial. Lancet 369 (9580): 2161–2170

    Article  PubMed  CAS  Google Scholar 

  10. Villa LL, Coasta RL, Petta CA et al (2005) Prophylactic quadrivalent human papillomavirus (types 6, 11, 16 and 18) L1-virus-like partricle vaccine in young women a randomised double-blind placebocontrolled multicentre phase II efficacy trial. Lancet Oncol 6: 271–278

    Article  PubMed  Google Scholar 

  11. Villa LL, Coasta RL, Petta CA et al (2006) High sustained efficacy of a prophylactic quadrivalent human papillomavirus types: 6/11/16/18 L1 virus-like particle vaccine through 5 years of follow-up. Br J Cancer 95: 1459–1466

    Article  PubMed  CAS  Google Scholar 

  12. Garland SM, Hernandez-Avila M, Wheeler CM et al (2007) Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N Engl J Med 356: 1928–1943

    Article  PubMed  CAS  Google Scholar 

  13. FUTURE II STUDY GROUP (2007) Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N Engl J Med 356: 1915–1927

    Article  Google Scholar 

  14. Harper DM, Franco EL, Wheeler CM et al (2006) Sustained efficacy up to 4,5 years pf a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial. Lancet 367 (9518): 1247–1255

    Article  PubMed  CAS  Google Scholar 

  15. Smith JF, Brownlow M, Brown M et al (2007) Antobodies from Women Immunized with Gardasil (®) Cross-Neutralize HPV 45 Pseudovirions. Hum Vaccin 3: 109–116

    Article  PubMed  CAS  Google Scholar 

  16. Petry KU, Hillemanns P, Gieseking F et al (2007) Direkte und indirekte Kostenbewertung HPV-assoziierter Erkrankungen (Genitalwarzen und zervikale Läsionen) in Deutschland, 15. Jahrestagung der Deutschen Gesellschaft für Pädriatische Infektiologie 2007, Basel, Poster P68

  17. Hillemanns P, Petry KU, McAllister R et al (2007) Vortrag zu: HPV (6, 11, 16 & 18)-Impfung als Primärprävention bei HPV-bedingten Erkrankungen — eine Kosteneffektivitätsanalyse in Deutschland (Informationsquelle: Sanofi MSD)

  18. Mendoza N, Paul O, Hernandez BA et al (2011) HPV vaccine update: new indications and controversies. http: //www.skintherapyletter.com/2011/16.8/1.html (01.03.2012, 18: 00)

  19. Moreira ED Jr, Palefsky JM, Giuliano AR et al (2011) Safety and reactogenicity of a quadrivalent human papillomavirus (types 6, 11, 16, 18) L1 viral-like-particle vaccine in older adolescents and young adults. Hum Vaccin 7: 768–775

    Article  PubMed  Google Scholar 

  20. Committee Opinion No. 467 (2010) Human papillomavirus vaccination. Obstet Gynecol 116: 800–803

    Article  Google Scholar 

  21. Lambert S, Selvey C (2012) Is this really an ethical evaluation of HPV vaccination policy in Australia? Aust NZ J Public Health 36: 96

    Article  Google Scholar 

  22. Shafi MI, Petry, Bosch U et al (2011) European consensus statement on “HPV vaccination and colposcopy”. J Low Genit Tract 15: 309–315

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, Universität zu Köln, Köln, Deutschland

    P. Mallmann

  2. Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe der Universität zu Köln, Kerpener Straße 62, 50924, Köln, Deutschland

    P. Mallmann

Authors
  1. P. Mallmann
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to P. Mallmann.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Mallmann, P. HPV-Impfung. best practice onkologie 7, 22–28 (2012). https://doi.org/10.1007/s11654-011-0378-6

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11654-011-0378-6

Search

Navigation